Pfizer Inc. (PFE) Stock: Price, Forecast & Analyst Target
Pfizer Inc. (PFE) — MoonshotScore 67/100 (Strong band), calculated Nov 18, 2026. Price $27.54 (-1.85%), as of the Nov 19, 2026 trading session; market cap $157B. Expected results Feb 2, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Pfizer Inc. · PFE · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Pfizer sells medicines and vaccines across oncology, cardiovascular care, infectious disease, rare disease, immunology and other therapeutic areas, chiefly through its Biopharma business. Its future depends on whether newer products, collaborations and manufacturing savings can counter pressure on established brands while preserving cash generation. Recent revenue and operating profit improved, but the latest period still ended in a net loss and produced much less operating cash than preceding periods.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Pfizer (PFE)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet and weak growth; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Fading; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 2, 2027
- Altman Z 2.14 · Piotroski F 7
Holding back: balance-sheet strain, soft growth
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 67 | Strong | |
| 67 | Strong | |
| 67 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $27.54 | |
| Change on the day | -1.85% | |
| 52-week range | $23.62–$31.44 | |
| Market capitalisation | $157B | — |
| Price / earnings (trailing) | 40.27 | |
| Shares traded on the day | 35.00M | |
| Beta (volatility vs the S&P 500) | 0.28 |
Why Pfizer scores 67
Share price, last 12 months +19.8%
$24.39 $29.23
What the price assumes
2.5% a year of free-cash-flow growth for ten years is what a $166.60B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $11.79B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 12 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 2.1% either way.
- -1.5%Jan ’24
- +8.1%May ’24
- -0.6%Jul ’24
- -1.2%Oct ’24
- +0.9%Feb ’25
- +5.9%Apr ’25
- +1.7%Aug ’25
- -0.2%Nov ’25
- +0.5%Feb ’26
- +0.9%May ’26
- +3.1%Aug ’26
- +0.4%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +0.4% | — | |
| Beat | Beat | +3.1% | +6.4% | |
| Beat | Beat | +0.9% | -1.6% | |
| Beat | Beat | +0.5% | +3.6% | |
| Beat | In line | -0.2% | +3.4% | |
| Beat | Beat | +1.7% | +4.8% | |
| Beat | Miss | +5.9% | -0.7% | |
| Beat | Beat | +0.9% | -2.6% | |
| Beat | Beat | -1.2% | -3.0% | |
| Beat | Beat | -0.6% | -4.6% | |
| Beat | Beat | +8.1% | +10.3% | |
| Beat | In line | -1.5% | +0.1% |
Beats have usually been rewarded — 8 of 12 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “phase study”, “innovent transaction”, “lyme disease”, “multiple myeloma” — none of them came up in Q2 FY2026.
- Getting louder: “breast cancer” (2 → 10 mentions), “long term” (3 → 6 mentions), “chronic weight” (1 → 4 mentions).
- Gone quiet: “phase iii”, “non-small cell”, “phase iib”, “high single-digit” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 67 to 67 while the share price moved -1.5% through .
The score has stayed in the Strong band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 40% of 40 rate it a buy; the average target sits +13.0% from the price of $27.54.
- Last 90 days: 10 rating actions, every one a reaffirmation.
- Our signals: Strong band; strongest pillar Business Quality (82), weakest Growth Durability (29).
Our signals are more constructive than the crowd, led by Business Quality.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Pfizer (PFE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Pfizer (PFE), and what does it report?
Short answer · as of
Pfizer develops, manufactures and distributes prescription drugs, biologics, vaccines, biosimilars, sterile injectables and anti-infectives.
Research dated 2026-09-12.
Demand arrives through prescriptions, administered doses and institutional purchases by wholesalers, pharmacies, hospitals, clinics, governments and public-health organizations; contract manufacturing adds a smaller activity alongside proprietary products and collaborations.
The breadth of the portfolio does not translate into a broad set of separately reported operating segments. Reported revenue is overwhelmingly assigned to Biopharma, with only a comparatively small corporate reconciling category, so the segment totals mainly measure the performance of one aggregated medicines-and-vaccines portfolio rather than distinct divisional businesses.
What do the latest results show for Pfizer (PFE)?
Research dated 2026-09-12.
The latest period delivered higher revenue, gross profit and operating profit than the immediately preceding period and the comparable earlier period. Yet the income statement moved from profit to loss as research and development and selling, general and administrative costs rose from the preceding period. Operating cash flow remained positive but weakened sharply, leaving only modest cash generation after capital spending.
The earnings figure tracked against market estimates remained positive and exceeded expectations, while the statutory income statement recorded a loss. Those presentations should not be treated as interchangeable. Management separately says manufacturing optimization is intended to lower production costs and deliver additional savings, but that is an outlook for future efficiency rather than an explanation for the latest accounting loss.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $16.58B Nov 3, 2026
- Latest report · revenue estimate
- $15.85B Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $16.58B | $15.85B | $0.8700 | $0.7350 |
| Aug 4, 2026 | $15.03B | $14.40B | $0.7700 | $0.6820 |
| May 5, 2026 | $14.45B | $13.84B | $0.7500 | $0.7220 |
| Feb 3, 2026 | $17.56B | $16.85B | $0.6600 | $0.5670 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $16.65B | $3.54B | $0.62 (diluted) |
| Q4 FY2025 | $17.56B | -$1.65B | -$0.29 (diluted) |
| Q1 FY2026 | $14.45B | $2.69B | $0.47 (diluted) |
| Q2 FY2026 | $15.03B | -$248M | -$0.04 (diluted) |
What are the financial strengths and risks for Pfizer (PFE)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Pfizer still generates substantial operating cash across the reporting cycle, and its trailing free-cash-flow yield is stronger than its trailing earnings yield. Liquidity also covers current liabilities on the broader current-asset measure, although the more restrictive quick measure is thinner.
Debt greatly exceeds cash and investments, while cash and short-term investments have declined across the latest consecutive reporting periods. That makes sustained cash conversion more important than headline profit alone. A setback across major brands such as Eliquis, Ibrance, Vyndaqel, Paxlovid, Comirnaty or Prevnar would feed directly into the dominant Biopharma revenue pool; contract manufacturing and corporate reconciling activity do not provide meaningful segment diversification.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 40.27 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Pfizer (PFE)?
Short answer · as of
The next earnings report is expected on Feb 2, 2027.
Research dated 2026-09-12.
The next earnings release should be read across revenue, statutory net income, the estimate-tracked earnings measure and operating cash flow. Recent estimate beats have not prevented volatility in statutory earnings or a sharp slowdown in cash generation, so confirmation requires those measures to improve together.
Watch whether manufacturing savings begin to appear in gross and operating margins, whether the cash balance stabilizes, and whether consensus revenue expectations stop moving downward across the longer forecast horizon. Management also expects the Vyndamax patent settlement to support cash flow beyond the nearer forecast period; until then, product performance and cost execution carry the burden.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Pfizer compare with its peers?
Short answer
Pfizer's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Pfizer combines mass-market vaccines and anti-infectives with oncology drugs, rare-disease therapies, cardiovascular medicines, biosimilars, sterile injectables and contract manufacturing. Its commercial exposure therefore spans pharmacy dispensing, hospital use, physician prescribing and government or public-health procurement, while collaborations place some products inside shared economics rather than a purely self-owned portfolio.
That operating variety is consolidated into an overwhelmingly Biopharma reporting structure. Comparisons based only on segment count can therefore misread Pfizer: the diversification lies inside its product portfolio, therapeutic areas, customers and partnerships, not across separately disclosed operating divisions.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1351.12 Nov 19, 2026 | $1.20T | 98 5-pillar Nov 18, 2026 | |
| $38.87 Nov 19, 2026 | $171B | 87 5-pillar Nov 18, 2026 | |
| $46.06 Nov 19, 2026 | $111B | 87 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $175.41 Nov 19, 2026 | $272B | 85 5-pillar Nov 18, 2026 | |
| $438.82 Nov 19, 2026 | $237B | 84 5-pillar Nov 18, 2026 | |
| $283.54 Nov 19, 2026 | $501B | 83 5-pillar Nov 18, 2026 | |
| $267.14 Nov 19, 2026 | $643B | 83 5-pillar Nov 18, 2026 | |
| $151.22 Nov 19, 2026 | $286B | 82 5-pillar Nov 18, 2026 | |
| $47.82 Nov 19, 2026 | $95.9B | 77 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $227.56 Nov 19, 2026 | $160B | 71 5-pillar Nov 18, 2026 | |
| Pfizer (PFE) — this page | $27.54 | $157B | 67 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $27.00 – $40.00
- Consensus target
- $31.50
- Median target
- $30.50
Consensus record · Captured .
Measured against a quoted price of $27.54 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 13, 2026
- Transactions
- 31
- Identified insiders
- 9
- Purchases
- 3
- Sales
- 2
- Other transactions
- 26
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PFE in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.06% | $13.63M | Added +165.4% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Pfizer (PFE)?
- Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027
- SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
- Pfizer Inc. (PFE) Rose 20% as COVID Revenue Declined: Is Its New Product Portfolio Driving a Turnaround?
What Investors Ask About Pfizer (PFE) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why can Pfizer beat earnings expectations while reporting a net loss?
The estimate-tracked earnings series and the statutory income statement present different earnings measures. In the latest period, the former was positive and above consensus while diluted statutory earnings and net income were negative, so the apparent contradiction comes from comparing unlike presentations.
How important is Pfizer contract manufacturing beside Biopharma?
Contract manufacturing broadens Pfizer’s activities, but the reported segment structure remains overwhelmingly Biopharma. It does not appear as a separately material segment in the disclosed revenue split.
What does the Vyndamax patent settlement mean for Pfizer cash flow?
Management expects the settlement to benefit cash flow beyond the nearer forecast period. It therefore supports the longer-term cash outlook but does not resolve the recent weakening in operating cash generation.
Can Pfizer manufacturing savings offset the expected revenue decline?
Manufacturing savings can lower cost of goods sold and support margins or cash flow, but they do not replace lost sales. The relevant test is whether margin improvement and cash conversion strengthen while consensus revenue expectations eventually stabilize.
What is the PFE stock price today?
The last price recorded for Pfizer Inc. (PFE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PFE price target?
The analyst consensus price target for Pfizer Inc. (PFE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold PFE
Funds in our ETF coverage that list PFE among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| PBPH ETF | 3.42% | |
| WisdomTree BioRevolution Fund (WDNA) | 2.50% | |
| Alger Russell Innovation ETF (INVN) | 2.39% | |
| LSV Disciplined Value ETF (LSVD) | 1.73% |
